The role of CD38 in TIICs is consistent with elevated CD38 in a number of hematological cancers and the clinical effectiveness of anti-CD38 monoclonal antibodies (e.g., daratumumab) in treating multiple myeloma (Van De Donk and Usmani, 2018). Here, CD38 is linked to hematopoietic and lymphoid cell neoplasm.